Insulet Corp Stock Price, News & Analysis

Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology, will release its second quarter 2025 financial results on August 7, 2025, before markets open. Management will host a conference call at 8:00 a.m. ET the same day.

The company specializes in the Omnipod Insulin Management System, featuring a unique tubeless disposable Pod that provides up to three days of continuous insulin delivery. Their flagship product, the Omnipod 5 Automated Insulin Delivery System, integrates with continuous glucose monitoring and can be controlled via smartphone in the U.S.

Insulet Corporation (PODD) will present extensive clinical data and real-world evidence for its Omnipod 5 Automated Insulin Delivery System at the American Diabetes Association's 85th Scientific Sessions from June 20-23, 2025. The company will share deeper insights from its groundbreaking SECURE-T2D trial for type 2 diabetes and RADIANT trial for type 1 diabetes, along with real-world evidence from over 23,000 type 2 diabetes patients. Key presentations include analysis of glycemic outcomes, diabetes distress reduction, and improved outcomes across baseline time-in-range levels. The conference activities feature panel discussions, oral presentations, and poster sessions led by prominent diabetes experts. Insulet's booth will host podcast recordings, hands-on demonstrations, and showcase a new comic book featuring a hero with type 1 diabetes.

Insulet Corporation (NASDAQ: PODD) has announced that its Omnipod 5 App for iPhone now integrates with the Dexcom G7 Continuous Glucose Monitoring System, expanding diabetes management capabilities for U.S. users. The integration allows users to control their tubeless insulin pump system directly from their iPhone, combining automated insulin delivery with Dexcom's latest CGM technology. The Omnipod 5 system automatically adjusts insulin delivery every five minutes, provides protection against high and low glucose levels, and enables users to perform functions like bolusing and Pod changes through the iPhone app. This advancement eliminates the need for a separate Controller device, offering greater convenience and simplified diabetes management.

Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami. The presentation is scheduled for June 10, 2025, at 9:20 a.m. ET. The company will provide a live audio webcast accessible through their investor relations website.

Insulet specializes in the Omnipod Insulin Management System, offering a unique tubeless disposable Pod that provides three days of continuous insulin delivery without needles. Their flagship product, the Omnipod 5 Automated Insulin Delivery System, integrates with continuous glucose monitors and can be controlled via smartphone in the U.S. or through the Omnipod 5 Controller.

Insulet Corporation (NASDAQ: PODD), a leader in tubeless insulin pump technology, has released its 2024 Sustainability Report highlighting significant ESG achievements. The company met 11% of its global electricity needs with renewable energy and installed over 5,700 solar panels at its Malaysia facility, covering 21% of the facility's electricity needs. The facility is designed to achieve GBI and LEED Silver certifications.

Key accomplishments include collecting 7.4 million Pods through global takeback programs and expanding access to Omnipod 5 internationally through integration with Abbott's FreeStyle Libre 2 Plus and Dexcom G7 sensors. The company also launched the Omnipod 5 App for iPhone and introduced "Insulet for Good," a global corporate giving program that exceeded employee engagement goals.

Insulet (NASDAQ: PODD) reported strong Q1 2025 financial results with revenue increasing 29% year-over-year to $569.0 million. The company's core Omnipod business generated $554.1 million in revenue, up 28%. U.S. Omnipod revenue grew 26.4% to $401.7 million, while International Omnipod revenue increased 32.2% to $152.4 million. Gross margin improved to 71.9%, up 240 basis points. The company reported net income of $35.4 million ($0.50 per diluted share). Key operational highlights include the expansion of Omnipod 5 to four new countries (Australia, Belgium, Canada, and Switzerland), positive RADIANT trial results showing improved glucose control, and a new $125 million stock repurchase program. The company raised its full-year 2025 guidance, now expecting total revenue growth of 19-22% and gross margin of ~71%.

Insulet (NASDAQ: PODD) has appointed Ashley McEvoy as President and CEO, effective immediately, replacing Jim Hollingshead who will cease employment on April 28, 2025. McEvoy brings nearly three decades of healthcare leadership experience, previously serving as Executive Vice President and Worldwide Chairman of Johnson & Johnson's MedTech business.

Under Hollingshead's leadership, Insulet launched Omnipod 5, achieving market leadership in type 1 diabetes in the U.S. and Europe, and became first-to-market in Automated Insulin Delivery for type 2 diabetes in the U.S. The company expects to exceed its Q1 2025 revenue guidance and plans to raise full-year 2025 guidance, with details to be announced on May 8, 2025.

Due to the leadership transition, Insulet has postponed its previously scheduled June 5, 2025 Investor Day to a later date.

Insulet (NASDAQ: PODD), the global leader in tubeless insulin pump technology, will release its first quarter 2025 financial results on May 8, 2025, after market close. Management will host a conference call at 4:30 p.m. (Eastern Time).

The company specializes in the Omnipod Insulin Management System, offering a tubeless disposable Pod that provides up to three days of continuous insulin delivery. Their flagship product, the Omnipod 5 Automated Insulin Delivery System, integrates with continuous glucose monitors and can be controlled via smartphone in the U.S. or through the Omnipod 5 Controller.

Insulet (NASDAQ: PODD) announced significant results from its RADIANT study of the Omnipod 5 Automated Insulin Delivery System. The multinational randomized controlled trial evaluated direct transition from multiple daily injections (MDI) to automated insulin delivery in type 1 diabetes patients.

Key findings from the 188-participant study showed:

• Average HbA1c reduction of -0.8% compared to MDI with continuous glucose monitor
• Additional 5.4 hours per day with glucose levels in target range (70-180mg/dL)
• Final average time in range improved to 65% from 39% baseline
• No life-threatening events or severe hypoglycemia reported

The study, conducted across 19 clinical centers in France, UK, and Belgium, included participants aged 4-70 years with HbA1c levels of 7.5% to 11%. Patients using Omnipod 5 with initial HbA1c above 8.0% showed even greater improvement of 1.0% compared to MDI plus CGM.